| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CARLSBAD, Calif.—Life Technologies Corp. hasannounced its entrance into a master development agreement with Bristol-MyersSquibb Co. for current and future companion diagnostics projects. This deal marksthe second collaboration between the two companies and represents what LifeTechnologies calls "another step in [the company's] strategy to develop itsdiagnostic business through internal development, partnerships and selectacquisitions"
 
 
The agreement reportedly covers an initial projectfor oncology and provides for a long-term partnership across a potentiallybroad range of Life Technologies instrument platforms and a wide range oftherapeutic areas.
 
 
"The pharmaceutical industry is increasinglyturning its focus to discovering and delivering targeted, personalizedmedications," said Ronnie Andrews, president of medical sciences at LifeTechnologies. "As more and more targeted drugs come onto the market in thenext decade, there will be a growing need for diagnostics that can help predictwhich patients will benefit from which drugs.
 
 
Life Technologies possesses a breadth of platformsthat can be leveraged in the development of new diagnostics. These platformsspan both genetic and proteomic analysis, including next-generation sequencing,Sanger sequencing, qPCR, flow cytometry and immuno-histochemistry. In addition,the company recently announced that its Ion Torrent Personal Genome Machine(PGM) would be developed for proteomics capabilities.
 
 
"For oncology alone, hundreds of agents arecurrently in clinical trials, and we see strong market opportunity in therobust expansion this will mean for the companion diagnostics space," saidAndrews.  "Life is uniquelypositioned to provide pharma a flexible, cost effective means to manage theevolution of the companion diagnostic assay through the drug developmentprocess."

SOURCE: Life Technologies
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue